SINO BIOPHARM: "TQC3721 (PDE3/4 inhibitor)", "TQC2731 (TSLP monoclonal antibody)" and a total of 3 research data will be announced at ERS 2024
I'm PortAI, I can summarize articles.
SINO BIOPHARM announced that it will showcase three research data on its two innovative drugs, "TQC3721 (PDE3/4 inhibitor)" and "TQC2731 (TSLP monoclonal antibody)", at the European Respiratory Society Annual Congress (ERS 2024) in 2024. TQC3721, an inhaled PDE3/4 inhibitor, has completed Phase I and Phase IIa clinical trials and will present its key abstract in poster form. TQC2731 is currently undergoing Phase II clinical trials, with its Phase I data also being released at the conference. This achievement marks a significant development for the company in the field of respiratory medicine
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments